Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
Wednesday, October 30, 2024 1 min read
Key Takeaway: Nautilus Biotechnology, Inc. announced its participation in the inaugural Guggenheim Healthcare Conference, scheduled for November 13, 2024. The company's management will engage in a fireside chat to discuss their pioneering single-molecule protein analysis platform. Interested parties can access a live and archived webcast through Nautilus's website. This event represents a strategic opportunity for Nautilus to increase visibility and support for its innovation in proteomics.
Market Sentiment Analysis
POSITIVE FACTORS
Participation in a significant healthcare conference
Opportunity to showcase innovative protein analysis platform
Fireside chat may enhance investor interest and engagement
Full Press Release Details
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.
Nautilus’ management is scheduled to participate in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.